Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 9/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | DHODH | Q02127 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13307945 | 0.95 | CNR1 (0.59) | CNR1KMT2AMEN1 | |
| SCHEMBL13307870 | 0.80 | CNR1 (0.92) | CNR1 | |
| SCHEMBL13308000 | 0.78 | CNR1 (0.69) | CNR1TSHR | |
| SCHEMBL13307992 | 0.77 | CNR1 (0.68) | CNR1TSHR | |
| SCHEMBL13307843 | 0.77 | CNR1 (0.59) | CNR1 | |
| SCHEMBL13307957 | 0.76 | CNR1 (0.74) | CNR1 | |
| SCHEMBL13307995 | 0.76 | CNR1 (0.66) | CNR1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL13307825 | 0.75 | CNR1 (1.00) | CNR1 | |
| SCHEMBL13307976 | 0.74 | CNR1 (0.63) | CNR1TSHR | |
| SCHEMBL8227985 | 0.74 | KMT2A (0.54) | KMT2AMEN1NPSR1SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8293773-B2 | 1, 2, 3-triazole derivatives as new cannabinoid-1 receptor antagonists | NATIONAL TSING HUA UNIVERSITY (TW) | 2012-10-23 | — | — | US | disclosed |
| US-8293773-B2 | 1, 2, 3-triazole derivatives as new cannabinoid-1 receptor antagonists | NATIONAL TSING HUA UNIVERSITY (TW) | 2012-10-23 | — | — | US | disclosed |
| US-20100144734-A1 | 1, 2, 3-Triazole derivatives as new cannabinoid-1 receptor antagonists | NATIONAL TSING HUA UNIVERSITY (TW) | 2010-06-10 | — | — | US | disclosed |
| US-20100144734-A1 | 1, 2, 3-Triazole derivatives as new cannabinoid-1 receptor antagonists | NATIONAL TSING HUA UNIVERSITY (TW) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144734-A1 | 1, 2, 3-Triazole derivatives as new cannabinoid-1 receptor antagonists | CNR1, CNR2, GPR3 | CNR1 1/4885KMT2A 3239/4885MEN1 2978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.